Elevance Health beat investor expectations in its latest earnings report and is adding new food-as-medicine initiatives.
Here are nine updates about the Indianapolis-based company Becker's has reported since June 21.
- Community Health Plan of Washington named Demetria Malloy, MD, its chief health officer and chief medical officer. Dr. Malloy joins the organization from Elevance Health, where she served as regional vice president and medical director/strategic physician executive focusing on the central and west regions of the U.S.
- Elevance Health is scaling new uses for artificial intelligence, CEO Gail Boudreaux told investors.
- Elevance Health is expecting many consumers who have lost Medicaid to transition to other forms of coverage, executives told investors. According to the company's second-quarter earnings report, Elevance Health lost 135,000 Medicaid members during the quarter.
- Elevance Health posted double-digit revenue growth and beat investor expectations in the second quarter of 2023, according to the company's earnings report. Total revenues in the second quarter were $43.7 billion, a 13 percent increase year over year.
- Arlington, Va., is the fittest city in America for the sixth year in a row, according to the 16th annual American College of Sports Medicine Fitness Index published July 18 alongside the Elevance Health Foundation.
- Elevance Health's Medicaid membership grew by over 50 percent during continuous coverage requirements, according to a report from KFF.
- Elevance Health achieved a drastic reduction in youth and young adult suicides through predictive modeling and clinical outreach. Becker's sat down with Jessica Chaudhary, MD, a medical director at Carelon Behavioral Health and director of the Suicide Prevention Program, to discuss why the company created the program and what it's achieved since launching in 2018.
- Elevance Health named Kofi Essel, MD, as its new food-as-medicine program director.
- GLP-1 drugs have shown short-term benefits for people with diabetes, but the long-term impact of the drugs is unclear, Ms. Boudreaux said in a Wall Street Journal report.